SCHEMBL2860000

SCHEMBL2860000

COc1ccc(Cn2c(=O)c3c(N)n(-c4cccc(F)c4)nc3c3ccccc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
P2RX4 Q99571 1/20 0.47
TP53 P04637 2/20 0.44
ALDH1A1 P00352 3/20 0.42
PIK3R1 P27986 1/20 0.42
PIK3CA P42336 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
BLM P54132 1/20 0.41
GABRA5 P31644 1/20 0.41
POLB P06746 2/20 0.40
THRB P10828 1/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HDAC1 Q13547 1/20 0.40
GAA P10253 3/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 2/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861360 0.93 P2RX4 (0.50) MAPTP2RX4TP53ALDH1A1SMN1; SMN2
SCHEMBL2864984 0.89 RECQL (0.51) P2RX4TP53ALDH1A1SMN1; SMN2BLM
SCHEMBL2871092 0.89 P2RX4 (0.54) MAPTP2RX4TP53ALDH1A1SMN1; SMN2
SCHEMBL2865419 0.87 HDAC1 (0.46) MAPTP2RX4TP53ALDH1A1SMN1; SMN2
SCHEMBL2870305 0.87 P2RX4 (0.46) MAPTP2RX4TP53ALDH1A1PIK3R1
SCHEMBL2870442 0.86 KMT2A (0.45) MAPTP2RX4TP53PIK3R1PIK3CA
SCHEMBL2868482 0.85 P2RX4 (0.50) MAPTP2RX4TP53ALDH1A1SMN1; SMN2
SCHEMBL2866936 0.84 KMT2A (0.52) MAPTP2RX4TP53ALDH1A1SMN1; SMN2
SCHEMBL2867302 0.84 P2RX4 (0.48) MAPTP2RX4TP53ALDH1A1SMN1; SMN2
SCHEMBL2860751 0.83 P2RX4 (0.44) MAPTP2RX4TP53ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 MAPT 4583/4885P2RX4 718/4885TP53 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.